Quantitative analysis of fibroblastic foci in usual interstitial pneumonia

Chest

Volumn 130, Issue 1, 2006, Pages 22-29

  Enomoto, Noriyuki ^a   Suda, Takafumi ^a,b   Kato, Mosato ^a   Kaida, Yusuke ^a   Nakamura, Jutaro ^a   Imokawa, Shiro ^a   Ida, Masaaki ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Collagen vascular disease; Fibroblastic foci; Idiopathic interstitial pneumonia; Quantitative analysis; Usual interstitial pneumonia

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; DISEASE SEVERITY; EVALUATION; FEMALE; FIBROBLASTIC FOCI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMAGE ANALYSIS; INTERSTITIAL PNEUMONIA; LUNG FIBROBLAST; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SURVIVAL;

EID: 33746379649     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.1.22     Document Type: Article

References (24)

1. Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29:S93-S97
2. Phan SH. Fibroblast phenotypes in pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29:S87-S92
3. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002; 122:286S-289S
4. Kun C III, Boldt J, King TE Jr, et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140:1693-1703
5. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138:1257-1265
6. Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci 2002; 7:d1743-d1761
7. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164:1025-1032
8. Nicholson AG, Fulford LG, Colby TV, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166:173-177
9. Cherniack RM, Colby TV, Flint A, et al. Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis: the BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1991; 144:892-900
10. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167:1410-1415
11. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157:1301-1315
12. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304
13. Nakamura Y, Chida K, Suda T, et al. Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:235-241
14. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction. Thorax 1999; 54(Suppl)1:S1-S14
15. Haslam PL, Turton CW, Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35:328-339
16. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124:1-8
17. Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135:26-34
18. Watters LC, Schwarz MI, Cherniack RM, et al. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135:696-704
19. Peterson MW, Monick M, Hunninghake GW. Prognostic role of eosinophils in pulmonary fibrosis. Chest 1987; 92:51-56
20. Hallgren R, Bjermer L, Lundgren R, et al. The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis: signs of eosinophil activation in the lung are related to impaired lung function. Am Rev Respir Dis 1989; 139:373-377
21. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151
22. Hammar SP, Winterbauer RH, Bockus D, et al. Endothelial cell damage and tubuloreticular structures in interstitial lung disease associated with collagen vascular disease and viral pneumonia. Am Rev Respir Dis 1983; 127:77-84
23. Wusirika R, Ferri C, Marin M, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis: a study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003; 120:596-606
24. Ihn H, Sato S, Fujimoto M, et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000; 119:203-209